Defining the undefinable: The challenges and opportunities for cell therapy IP

IP strategy for cell therapies presents unique challenges compared to traditional pharmaceuticals and biologics. Previous posts have highlighted the limitations of process patents in cell therapy (IPKat) and the need to think strategically about how best to protect the product from fast-follower competition (IPKat). This post focusses on an even more fundamental challenge, that of the inherent